Conclusions  These results suggest that buprenorphine and buprenorphine/naloxone have similar abuse potential in non-dependent opioid abusers,
and that the addition of naloxone at these doses and in this dose ratio confers no evident advantage for decreasing the abuse
potential of intramuscular or sublingual buprenorphine in this population.

Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-010-1898-4Authors
Angela N. Duke, The Johns Hopkins University School of Medicine Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences 5510 Nathan Shock Drive Baltimore MD 21224 USAChristopher J. Correia, The Johns Hopkins University School of Medicine Behavioral Pharmacology Research Unit, Department of Psychiatry and…

Conclusions  These results suggest that buprenorphine and buprenorphine/naloxone have similar abuse potential in non-dependent opioid abusers,
and that the addition of naloxone at these doses and in this dose ratio confers no evident advantage for decreasing the abuse
potential of intramuscular or sublingual buprenorphine in this population.

Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-010-1898-4Authors
Angela N. Duke, The Johns Hopkins University School of Medicine Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences 5510 Nathan Shock Drive Baltimore MD 21224 USAChristopher J. Correia, The Johns Hopkins University School of Medicine Behavioral Pharmacology Research Unit, Department of Psychiatry and…

Abstract: Despite data supporting its efficacy, barriers to implementation of buprenorphine for office-based treatment are present. Complications can occur during buprenorphine inductions, yet few published studies have examined this phase of treatment. To examine factors associated with complications during buprenorphine induction, we conducted a retrospective chart review of the first 107 patients receiving buprenorphine treatment in an urban community health center. The primary outcome, defined as complicated induction (precipitated or protracted withdrawal), was observed in 18 (16.8%) patients. Complicated inductions were associated with poorer treatment retention (than routine inductions) and decreased over time. Factors independently associated with complicated inductions included re…

Abstract: Despite data supporting its efficacy, barriers to implementation of buprenorphine for office-based treatment are present. Complications can occur during buprenorphine inductions, yet few published studies have examined this phase of treatment. To examine factors associated with complications during buprenorphine induction, we conducted a retrospective chart review of the first 107 patients receiving buprenorphine treatment in an urban community health center. The primary outcome, defined as complicated induction (precipitated or protracted withdrawal), was observed in 18 (16.8%) patients. Complicated inductions were associated with poorer treatment retention (than routine inductions) and decreased over time. Factors independently associated with complicated inductions included re…